Vivos Therapeutics, Inc. - 10-Q Filing

Vivos Therapeutics reports Q3 financial results including details on March 2026 PIPE offering and Series B non-convertible preferred stock issuance.

SEC EDGAR ·

Tickers: $VVOS

Read the full article at SEC EDGAR

More Regulatory news